Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials

Anandita Agarwala, Anne Goldberg

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in women across all racial and ethnic groups within the USA. Despite robust evidence from randomized controlled trials demonstrating that treatment of hypercholesterolemia in women reduces cardiovascular events, women who are eligible for lipid-lowering therapy are less likely than men to be prescribed guideline-recommended therapy or to have therapy prescribed at the appropriate intensity. Recent Findings: Historically, women have been underrepresented in clinical trials. Recent randomized clinical trials have shown that women derive similar benefits as men when treated with lipid-lowering therapy, and recent studies demonstrate potential uses for lipid-lowering therapies that extend beyond their previously well-established indications. Summary: In this review, we will discuss lipid-lowering therapies in the context of recent clinical trials with a focus on special considerations in women.

Original languageEnglish
Article number42
JournalCurrent Atherosclerosis Reports
Issue number8
StatePublished - Aug 2021


  • Atherosclerotic cardiovascular disease
  • Lipid-lowering
  • Pre-eclampsia
  • Women


Dive into the research topics of 'Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials'. Together they form a unique fingerprint.

Cite this